This treatment acts independently of β-cell function or insulin sensitivity, thereby suggesting an alternative or complementary approach to currently available treatments and offering an additional therapeutic option throughout the natural history of type 2 diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.